Filter News

Saladax Biomedical Inc. (SBI) Issued Six Patents Containing Broad Claims in the Immunoassay Space

Published: Jan 11, 2012

BETHLEHEM, Pa., Jan. 10, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that it has been issued six patents within the last 12 months, bringing the company's total to 15 issued U.S. patents, all of which contain broad claims in the immunoassay space. The issued patents are as follows:

  • Busulfan Immunoassay: U.S. Patent No. 7,893,220
  • Stabilized Standards for Busulfan Immunoassay: U.S. Patent No. 8,039,220
  • Doxorubicin Immunoassay: U.S. Patent No. 8,053,205
  • Imatinib Immunoassay: U.S. Patent No. 8,076,097
  • Doxorubicin Immunoassay: U.S. Patent No. 8,084,586
  • Resperidone Immunoassay: U.S. Patent No. 8,088,594

"The issuance of these patents in the U.S. positions Saladax as the leader in chemotherapy dose management and we believe that Saladax has been issued more patents in the therapeutic dose management (TDM) space than any other diagnostic company," said Salvatore J. Salamone, founder and CSO of Saladax. "Of particular note, our patent for Resperidone marks a significant milestone for Saladax as this is our first patent in the CNS field."

About My5-FU

Saladax's first commercially available test for innovative dose management, My5-FU, measures levels of 5-fluorouracil (5-FU), a widely prescribed chemotherapy drug used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors. The assay technology enables oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and other side effects.

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics. The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life. The Company's 15 MyCare dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology. The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU). This assay is sold by Saladax in Europe as a CE-marked product and will be distributed in Japan by FALCO biosystems. In the United States and Canada, Myriad Genetic Laboratories, Inc. provides testing for 5-FU dose optimization under the trademark OnDose® through a license to Saladax proprietary technology. In addition the company is finalizing development of its next two oncology drug assays for paclitaxel and docetaxel. Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds. For more information, visit www.saladax.com, or follow us on Twitter at https://twitter.com/Saladax.

Saladax Biomedical, Inc.
Edward L. Erickson
President and Chief Executive Officer
eerickson@saladax.com

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
amielach@tiberend.com
or
Jason Rando
jrando@tiberend.com

SOURCE Saladax Biomedical, Inc.

Back to news